Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • MMJ Group’s (MMJ) largest investee, Embark Health, has signed its first business-to-business sale of Bulk Bubble Hash, a cannabis extraction product
  • The sale comes after production commenced at Embark’s facility in Delta, British Columbia
  • Embark says that this is the first of several upcoming business-to-business sales agreements
  • MMJ Group currently holds a 12.7 per cent stake in Embark, with several options to increase its interest in the future
  • At market open, the company is trading flat for 12 cents per share

MMJ Group’s (MMJ) largest investee, Embark Health, has signed its first business-to-business (B2B) sale of Bulk Bubble Hash, a cannabis extraction product.

Based in Delta, British Columbia, Embark Health operates in the growing cannabis extraction space, manufacturing a range of products for both recreational and medical markets around the world.

In early February this year, Embark received its license from Health Canada for the production of cannabis extracts at its 40,000 square foot processing facility. With this secured, the company is now turning its attention to revenue generation.

This latest sale is the first of several business-to-business sales agreements. These will initially be focused on Bubble Hash, Dry Sift Kief and Rosin, as well as third-party white-label services. However, Embark plans to add further extraction techniques as the capabilities of its facility progress.

“We are thrilled to have signed our first sale agreement as we ramp up production in Delta,” said Dr Luc Duchesne, CEO of Embark Health.

“There is demand for 2.0 products and Embark Health offers a comprehensive portfolio of solventless extraction modalities and products to our clients,” he added.

MMJ Group has been involved with Embark since July 2018, when it came on board as a foundation investor. MMJ currently holds 3.425 million shares in the company, representing approximately 12.7 per cent, with a book value of C$2.40 per share.

MMJ also holds a number of share purchase warrants, entitling it to acquire up to an additional 3.325 million shares at various exercise prices. 

As of April 30, 2020, MMJ had doubled its original investment in Embark Health. The company says that this is testament to its ability to originate early-stage unlisted investments within the cannabis sector.

At market open, the company is trading flat for 12 cents per share.

MMJ by the numbers
More From The Market Herald

" Spheria (ASX:SEC) announces initial quarterly fully franked dividend of 2.5 cents

Spheria Emerging Companies (SEC) says it will pay shareholders an initial quarterly dividend of 2.5 cents per share for the period ended Septembe…
Pendal Group (ASX:PDL) - CEO and MD, Nick Good

" Pendal Group (ASX:PDL) ends September with increased $139b FUM

Pendal Group (PDL) is releasing its latest quarterly update, revealing it had an increased $139.2 billion worth of funds under management (FUM).
Dimerix (ASX:DXB) - Managing Director and CEO, Nina Webster

" Dimerix (ASX:DXB) expands DMX-200 study into Australia

Dimerix (DXB) has entered an agreement with the NHMRC Clinical Trials Centre at the University of Sydney to expand the CLARITY 2.
DomaCom (ASX:DCL) - CEO, Arthur Naoumidis

" DomaCom (ASX:DCL) reaches key milestone in AustAgri acquisition

Fractional investing platform provider DomaCom (DCL) soldiers in on its thorny acquisition deal of AustAgri, announcing a key condition of the transaction has